Pressure BioSciences, Inc.
PBIO
$0.0031
-$0.002-39.22%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -17.58% | -52.84% | -48.55% | 186.81% | 2.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.58% | -52.84% | -48.55% | 186.81% | 2.75% |
| Cost of Revenue | 47.12% | -34.94% | -73.77% | 81.85% | -15.06% |
| Gross Profit | -82.64% | -69.66% | 96.81% | 931.46% | 30.20% |
| SG&A Expenses | 58.72% | -62.93% | 393.24% | 6.19% | 14.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.51% | -58.12% | 76.57% | 13.16% | 13.82% |
| Operating Income | -78.32% | 59.19% | -125.68% | 5.18% | -19.95% |
| Income Before Tax | -2.80% | -17.74% | -122.14% | -26.17% | -137.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.80% | -17.74% | -122.14% | -26.17% | -137.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.80% | -17.74% | -122.14% | -26.17% | -137.38% |
| EBIT | -78.32% | 59.19% | -125.68% | 5.18% | -19.95% |
| EBITDA | -74.56% | 60.97% | -131.62% | 6.84% | -20.46% |
| EPS Basic | 73.60% | 52.48% | 13.76% | 34.42% | -78.38% |
| Normalized Basic EPS | 70.11% | 63.69% | 62.12% | 15.19% | -36.95% |
| EPS Diluted | 73.60% | 52.48% | 13.76% | 34.42% | -78.38% |
| Normalized Diluted EPS | 70.11% | 63.69% | 62.12% | 15.19% | -36.95% |
| Average Basic Shares Outstanding | 164.04% | 151.34% | 149.81% | 95.09% | 86.10% |
| Average Diluted Shares Outstanding | 164.04% | 151.34% | 149.81% | 95.09% | 86.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |